Tasigna and Pacemaker generated arrhythmia - a phase IV clinical study of FDA data

Summary:

We study 31,590 people who take Tasigna (nilotinib hydrochloride monohydrate) or have Pacemaker generated arrhythmia. No report of Pacemaker generated arrhythmia is found in people who take Tasigna.

The phase IV clinical study is created by eHealthMe based on reports from the FDA, and is updated regularly.

What is Tasigna?

Tasigna has active ingredients of nilotinib hydrochloride monohydrate. It is often used in chronic myelogenous leukemia (cml). eHealthMe is studying from 31,535 Tasigna users. Check the latest studies of Tasigna.

What is Pacemaker Generated Arrhythmia?

Pacemaker generated arrhythmia is found to be associated with 15 drugs and 85 conditions by eHealthMe. Check the latest studies of Pacemaker generated arrhythmia.

On Jun, 17, 2026

No report is found.

Do you take Tasigna and have Pacemaker generated arrhythmia?

- Check whether Pacemaker generated arrhythmia is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Tasigna:

Tasigna (31,535 reports)

Pacemaker generated arrhythmia treatments and more:

Pacemaker generated arrhythmia (55 reports)

How severe was Pacemaker generated arrhythmia and when was it recovered:

Pacemaker generated arrhythmia in Tasigna

Expand to all the drugs that have ingredients of nilotinib hydrochloride monohydrate:

Pacemaker generated arrhythmia and drugs with ingredients of nilotinib hydrochloride monohydrate

Browse all side effects of Tasigna:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Pacemaker generated arrhythmia:

Pacemaker generated arrhythmia

Browse all the conditions that are associated with Pacemaker generated arrhythmia:

Pacemaker generated arrhythmia

How the study uses the data?

The study uses data from the FDA. It is based on nilotinib hydrochloride monohydrate (the active ingredients of Tasigna) and Tasigna (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.